z-logo
Premium
Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma
Author(s) -
Myers Regina M.,
Hill Brian T.,
Shaw Bronwen E.,
Kim Soyoung,
Millard Heather R.,
Battiwalla Minoo,
Majhail Navneet S.,
Buchbinder David,
Lazarus Hillard M.,
Savani Bipin N.,
Flowers Mary E. D.,
D'Souza Anita,
Ehrhardt Matthew J.,
Langston Amelia,
Yared Jean A.,
Hayashi Robert J.,
Daly Andrew,
Olsson Richard F.,
Inamoto Yoshihiro,
Malone Adriana K.,
DeFilipp Zachariah,
Margossian Steven P.,
Warwick Anne B.,
Jaglowski Samantha,
Beitinjaneh Amer,
Fung Henry,
Kasow Kimberly A.,
Marks David I.,
Reynolds Jana,
StockerlGoldstein Keith,
Wirk Baldeep,
Wood William A.,
Hamadani Mehdi,
Satwani Prakash
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31114
Subject(s) - medicine , total body irradiation , lymphoma , diffuse large b cell lymphoma , population , transplantation , oncology , hematopoietic stem cell transplantation , international prognostic index , confidence interval , chemotherapy , surgery , cyclophosphamide , environmental health
BACKGROUND Autologous hematopoietic cell transplantation (auto‐HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell lymphoma (DLBCL); however, long‐term outcomes are not well described. METHODS This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression‐free for ≥2 years after auto‐HCT for cHL or DLBCL between 1990 and 2008. The median age at auto‐HCT was 40 years; the median follow‐up was 10.6 years. RESULTS The 5‐year overall survival rate was 90% (95% confidence interval [CI], 87%‐92%) for patients with cHL and 89% (95% CI, 87%‐91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6‐fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4‐fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto‐HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. CONCLUSIONS Despite generally favorable outcomes, 2‐year survivors of auto‐HCT for cHL or DLBCL have an excess late‐mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816‐25 . © 2017 American Cancer Society .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here